View Post

OncoSec Announces Publication in Clinical Cancer Research of Data Supporting the Therapeutic Potential of Lead Product Candidate, TAVO™, in Triple Negative Breast Cancer

In Clinical Studies News by Barbara Jacoby

From: finance.yahoo.com — TAVO intratumoral therapy was safe and effective at increasing tumor antigen specific presentation and recruitment of CD8+ T cells, indicating ability to generate robust anti-cancer immune response — — TAVO treatment-related CXCR3 gene signature associated with improved outcomes and conversion of non-responsive tumors; Future studies of TAVO with chemokines to assess anti-tumor immunity – OncoSec Medical Incorporated …

View Post

OncoSec Expands KEYNOTE-890 Trial into First-Line Metastatic Triple Negative Breast Cancer (mTNBC) with TAVO™ and KEYTRUDA® Plus Chemotherapy

In Clinical Studies News by Barbara Jacoby

From: biospace.com OncoSec Medical Inc. (NASDAQ:ONCS) (the “Company” or “OncoSec”), a company developing late-stage intratumoral cancer immunotherapies, today announced that, based upon tumor regression and associated clinical responses observed in the heavily pretreated Cohort 1 of the KEYNOTE-890 study, the Company plans to expand into earlier first-line treatment to investigate the combination of OncoSec’s lead product candidate TAVO™ (plasmid-based interleukin-12 or …